rs12439872 - FAM81A

Magnitude 2.2 · 1 study on file

Reported associations

• Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy. - Annals of the rheumatic diseases (2023) · Alonso N, Albagha OME, Azfer A, Larraz-Prieto B, Berg K, Riches PL, Ostanek B, Kocjan T, Marc J, Langdahl BL, Ralston SH · PubMed 36941031

  Teriparatide (TPTD) is an effective treatment for osteoporosis but the individual response to therapy is variable for reasons that are unclear. This study aimed to determine whether the response to TPTD might be influenced by genetic factors. We searched for predictors of the response of bone mineral density (BMD) to TPTD using a two-stage genome-wide association study in 437 patients with osteoporosis from three referral centres. Demographic and clinical data including the response of BMD to treatment at the lumbar spine and hip were extracted from the medical records of each participant. Allelic variation at rs6430612 on chromosome 2, close gene was associated with the response of spine BMD to TPTD at a genome wide significant level (p=9.2×10 beta=-0.35 (-0.47 to -0.23)). The increase i

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.